MNG68
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.516
- INFLAMMATORY_RESPONSE+0.488
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.426
- IL6_JAK_STAT3_SIGNALING+0.414
- INTERFERON_GAMMA_RESPONSE+0.413
- KRAS_SIGNALING_UP+0.367
- COMPLEMENT+0.355
- SPERMATOGENESIS+0.328
- COAGULATION+0.285
- PANCREAS_BETA_CELLS+0.262
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.447
- DNA_REPAIR-0.423
- MYC_TARGETS_V2-0.417
- PROTEIN_SECRETION-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.341
- MYC_TARGETS_V1-0.290
- NOTCH_SIGNALING-0.251
- PEROXISOME-0.210
- CHOLESTEROL_HOMEOSTASIS-0.206
- HEDGEHOG_SIGNALING-0.185
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168533 | — | — | 0.858 |
| 2 | TCGA-49-4487-01A-21R-1858-07 | — | cohortMD2 | 0.856 |
| 3 | SRR615467 | GTEX | — | 0.853 |
| 4 | MNG728 | — | — | 0.852 |
| 5 | SRR1474795 | GTEX | — | 0.850 |
| 6 | SRR1445238 | GTEX | — | 0.850 |
| 7 | MNG276 | — | — | 0.849 |
| 8 | SRR23303766 | — | — | 0.848 |
| 9 | MNG1166 | — | — | 0.847 |
| 10 | MDT-AP-2621 | Med | Medulloblastoma | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.516 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.488 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.426 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.414 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.413 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.367 | Inavolisib | — uncovered |
| COMPLEMENT | 0.355 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.328 | Inavolisib | — uncovered |
| COAGULATION | 0.285 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.262 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.258 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.228 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.204 | Inavolisib | — uncovered |
| HYPOXIA | 0.188 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.176 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.164 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.153 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.143 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.126 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.111 | Idelalisib | — uncovered |